Inter-observer variance and the need for standardization in the morphological classification of myelodysplastic syndrome.

[1]  Morteza Babaie,et al.  Pan-cancer diagnostic consensus through searching archival histopathology images using artificial intelligence , 2019, npj Digital Medicine.

[2]  D. Banerjee,et al.  Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS. , 2017, Blood cells, molecules & diseases.

[3]  A. Seegmiller,et al.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics , 2017, Current Hematologic Malignancy Reports.

[4]  L. Godley,et al.  Germline ETV6 mutations and predisposition to hematological malignancies , 2017, International Journal of Hematology.

[5]  Anna L. Brown,et al.  Myeloid neoplasms with germline DDX41 mutation , 2017, International Journal of Hematology.

[6]  T. Fioretos,et al.  Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. , 2017, Blood.

[7]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[8]  H. Okano,et al.  SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7 , 2016, Nature Genetics.

[9]  O. Abdel-Wahab,et al.  Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis , 2016, Genes & development.

[10]  A. Tefferi,et al.  Myelodysplastic syndromes: Contemporary review and how we treat , 2016, American journal of hematology.

[11]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[12]  S. Miyano,et al.  Inherited and Somatic Defects in DDX41 in Myeloid Neoplasms. , 2015, Cancer cell.

[13]  V. Raina,et al.  Picking up myelodysplastic syndromes and megaloblastic anemias on peripheral blood: use of NEUT‐X and NEUT‐Y in guiding smear reviews , 2015, International Journal of Laboratory Hematology.

[14]  Christopher C. Porter,et al.  Germline mutations in ETV6 are associated with thrombocytopenia, red cell macrocytosis and predisposition to lymphoblastic leukemia , 2015, Nature Genetics.

[15]  P. Campbell,et al.  Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes , 2014, Leukemia.

[16]  B. Bain,et al.  Proposal for refining the definition of dysgranulopoiesis in acute myeloid leukemia and myelodysplastic syndromes. , 2014, Leukemia research.

[17]  U. Germing,et al.  Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Düsseldorf Registry on myelodysplastic syndromes. , 2012, Leukemia research.

[18]  Gerhard Ehninger,et al.  Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors , 2012, Haematologica.

[19]  R. Colella,et al.  Understanding and recognizing the Pelger-Huët anomaly. , 2012, American journal of clinical pathology.

[20]  P. Font,et al.  Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification , 2012, Annals of Hematology.

[21]  A. D. Di Palma,et al.  Possibility of myelodysplastic syndromes screening using a complete blood automated cell count. , 2011, Leukemia research.

[22]  Z. Estrov,et al.  Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. , 2011, Blood.

[23]  M. Carvalho,et al.  Acquired Pelger-Huët: what does it really mean? , 2010, Clinica chimica acta; international journal of clinical chemistry.

[24]  M. Tomonaga,et al.  Proposals for a Grading System for Diagnostic Accuracy of Myelodysplastic Syndromes , 2008 .

[25]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.